Molecular Historical Income Statement
| MOLN Stock | USD 4.28 0.10 2.39% |
Historical analysis of Molecular Partners income statement accounts such as Total Revenue of 6.7 M can show how well Molecular Partners AG performed in making a profits. Evaluating Molecular Partners income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Molecular Partners's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Molecular Partners latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Molecular Partners is a good buy for the upcoming year.
Molecular |
About Molecular Income Statement Analysis
Molecular Partners Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Molecular Partners shareholders. The income statement also shows Molecular investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Molecular Partners Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts Molecular Partners generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of Molecular Partners AG minus its cost of goods sold. It is profit before Molecular Partners operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Molecular Partners. It is also known as Molecular Partners overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most accounts from Molecular Partners' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Molecular Partners current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Molecular Partners AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. At this time, Molecular Partners' Net Interest Income is very stable compared to the past year. As of the 7th of June 2024, Interest Income is likely to grow to about 4 M, while Depreciation And Amortization is likely to drop about 2.1 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 548K | 605K | 49K | 46.6K | Depreciation And Amortization | 2.7M | 3.5M | 2.4M | 2.1M |
Molecular Partners income statement Correlations
Click cells to compare fundamentals
Molecular Partners Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Molecular Partners income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 4.0M | 3.2M | 2.7M | 3.5M | 2.4M | 2.1M | |
| Interest Expense | 27K | 271K | 548K | 605K | 49K | 46.6K | |
| Selling General Administrative | 13.2M | 11.0M | 16.9M | 21.8M | 19.0M | 12.2M | |
| Total Revenue | 20.4M | 9.3M | 9.3M | 189.6M | 7.0M | 6.7M | |
| Gross Profit | (23.1M) | (46.7M) | (46.4M) | 138.8M | (40.8M) | (38.8M) | |
| Other Operating Expenses | 57.0M | 67.7M | 72.7M | 72.9M | 68.1M | 55.6M | |
| Operating Income | (36.7M) | (58.3M) | (63.4M) | 116.6M | (61.1M) | (58.1M) | |
| Ebit | (36.7M) | (58.3M) | (63.4M) | 116.6M | (61.1M) | (58.1M) | |
| Research Development | 43.5M | 56.1M | 55.7M | 50.7M | 46.7M | 42.7M | |
| Ebitda | (32.7M) | (55.1M) | (60.8M) | 120.1M | (58.7M) | (55.8M) | |
| Cost Of Revenue | 43.5M | 56.1M | 55.7M | 50.7M | 47.8M | 30.4M | |
| Total Operating Expenses | 57.0M | 67.7M | 72.7M | 72.9M | 65.7M | 55.4M | |
| Income Before Tax | (36.3M) | (62.8M) | (63.8M) | 117.9M | (62.0M) | (58.9M) | |
| Total Other Income Expense Net | 389K | (4.4M) | (365K) | 1.2M | (876K) | (919.8K) | |
| Net Income | (36.3M) | (62.8M) | (63.8M) | 117.9M | (62.0M) | (58.9M) | |
| Income Tax Expense | 17K | (11K) | 2K | (1.2M) | (1.1M) | (1.1M) | |
| Net Interest Income | 1.5M | 64K | (457K) | 523K | 3.7M | 3.9M | |
| Interest Income | 1.6M | 367K | 99K | 1.1M | 3.8M | 4.0M | |
| Net Income From Continuing Ops | (36.3M) | (62.8M) | (63.8M) | 117.9M | (59.6M) | (56.7M) | |
| Reconciled Depreciation | 2.5M | 2.9M | 2.6M | 2.4M | 2.4M | 2.3M | |
| Net Income Applicable To Common Shares | (36.3M) | (62.8M) | (63.8M) | 117.9M | 135.5M | 142.3M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Information and Resources on Investing in Molecular Stock
When determining whether Molecular Partners offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Molecular Partners' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Molecular Partners Ag Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Molecular Partners Ag Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Molecular Partners AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Molecular Partners. If investors know Molecular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Molecular Partners listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.99) | Revenue Per Share 0.205 | Quarterly Revenue Growth (0.10) | Return On Assets (0.18) | Return On Equity (0.30) |
The market value of Molecular Partners is measured differently than its book value, which is the value of Molecular that is recorded on the company's balance sheet. Investors also form their own opinion of Molecular Partners' value that differs from its market value or its book value, called intrinsic value, which is Molecular Partners' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Molecular Partners' market value can be influenced by many factors that don't directly affect Molecular Partners' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Molecular Partners' value and its price as these two are different measures arrived at by different means. Investors typically determine if Molecular Partners is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Molecular Partners' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.